Fibrinogen degradation products in patients with the Quebec platelet disorder Journal Articles

abstract

• The Quebec platelet disorder is a serious bleeding disorder associated with proteolysis of α‐granular proteins, including fibrinogen. We evaluated fibrinogen degradation product (FDP) assays as screening tests for this disorder. Patients with the Quebec platelet disorder (13/13) had elevated serum FDPs (P <0.01) due to secreted degraded platelet fibrinogen, but normal plasma FDPs and D‐dimers. Unrelated controls with bleeding disorders (32/34) had undetectable FDPs, and controls with FDPs due to disseminated intravascular coagulation (DIC) and other illnesses (11/11) had elevated FDPs in all assays (P < 0.01). Immunoblot analyses indicated plasma fibrinogen was normal in the Quebec patients and platelet FDPs were found in their platelet lysates, releasates and serum samples. Their platelet FDPs were not altered by treatment with fibrinolytic inhibitors and were different from the FDPs in DIC and in plasmin‐digested fibrinogen. Tests for serum FDPs may provide a simple rapid way to screen for the Quebec platelet disorder.

authors

• Hayward, Catherine Pauline Ma
• Welch, B
• Bouchard, M
• Zheng, S
• Rivard, GE

status

• published 

publication date

• May 1997

has subject area

• 1102 Cardiorespiratory Medicine and Haematology (FoR)
• Antifibrinolytic Agents (MeSH)
• Blood Coagulation Disorders (MeSH)
• Blood Platelet Disorders (MeSH)
• Fibrin Fibrinogen Degradation Products (MeSH)
• Fibrinogen (MeSH)
• Humans (MeSH)
• Immunoblotting (MeSH)
• Immunology (Science Metrix)

published in

• British Journal of Haematology  Journal

keywords

• Antifibrinolytic Agents
• Blood Coagulation Disorders
• Blood Platelet Disorders
• Fibrin Fibrinogen Degradation Products
• Fibrinogen
• Humans
• Immunoblotting

Digital Object Identifier (DOI)

• 10.1046/j.1365-2141.1997.862903.x

PubMed ID

• 9163623

start page

• 497

end page

• 503

volume

• 97

issue

• 2